HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular Targeted Cancer Therapy.

HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular Targeted Cancer Therapy. Cancer Invest. 2020 Apr 10;:1-34 Authors: Jafari A, Rezaei-Tavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H Abstract Heat shock protein 90 (HSP90), a highly and unique chaperone, presents as a double-edged sword. It plays an essential role in many physiological and pathological processes, including tumor development. The current review highlights a recent understanding of the roles of HSP90 in molecular mechanisms underlying cancer survival and progression. HSP90 and its client proteins through the regulation of oncoproteins including signaling proteins, receptors and transcriptional factors involved in tumorigenesis. It also has potential clinical application as diagnostic and prognostic biomarkers for assessing cancer progression. In this way, using HSP90 to develop new anti-cancer therapeutic agents including HSP90 inhibitors, anti-HSP90 antibody, and HSP90-based vaccines has been promising. PMID: 32274949 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research